Qlife has successfully verified the biomarkers related to the previously announced LOI

Qlife is pleased to announce that, in collaboration with Hipro Biotechnology, the company has successfully verified biomarkers related to the LOI with a top-20 global pharma company that was announced on January 28th.  

On 28 January 2025, Qlife signed a Letter of Intent (LOI) with a top-20 global pharmaceutical company to explore potential commercial collaborations. Among the key criteria outlined in the LOI was Qlife’s ability to test and integrate specific biomarkers into the Egoo Health platform. The company has now successfully verified these biomarkers, generating positive data. This confirmation demonstrates that the biomarkers covered in the LOI are compatible with the Egoo Health platform, reinforcing the feasibility of their integration.

“We look forward to presenting these data and expect that this will further advance discussions toward a partnership. As always, further validation of the biomarkers is required, and other parameters still need to be confirmed. However, it is very positive that the biomarkers have been fundamentally proven on the platform.”- says Thomas Warthoe, CEO Qlife.

About Egoo Health

Egoo Health enables advanced clinical-grade biomarker testing at home. The aim is to give people access to important health data at the clinical-grade level. Egoo Health is an integrated platform, consisting of a small diagnostic device, a blood-to-plasma collector, a disposable capsule that contain test reagents for a specific biomarker and the Egoo smartphone app that operates the system and can share data with health authorities.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34